ConductScience.org, home

Paper36545708

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.

Xie D and 4 others. Clin Mol Hepatol, 2023. Cited by 166 papers, by iCite.

Cite this record

ConductScience Library. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. Papers, record 36545708. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36545708

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.
PubMed
Journal
Clin Mol Hepatol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
166
iCite
Relative citation ratio, by iCite
17.5
iCite
Revised in PubMed
2023-07-24
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xie DDiyang
2Shi JJieyi
3Zhou JJian
4Fan JJia
5Gao QQiang

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Humans
Male
Sorafenib
Bevacizumab

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82130077National Natural Science Foundation of ChinaPubMed
82090053National Natural Science Foundation of ChinaPubMed
81961128025National Natural Science Foundation of ChinaPubMed
21JC1410100Science and Technology Commission of Shanghai MunicipalityPubMed
21JC1401200Science and Technology Commission of Shanghai MunicipalityPubMed
20JC1418900Science and Technology Commission of Shanghai MunicipalityPubMed

Source PubMed

Download CSV of grants

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in36924120The clinical management of hepatocellular carcinoma in China: Progress and challenges.https://conductscience.org/library/papers/36924120PubMed
Comment in36924123Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.https://conductscience.org/library/papers/36924123PubMed

Download CSV of comments and corrections

References75

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112673442Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).J Gastroenterol2003https://conductscience.org/library/papers/12673442PubMed
235464283Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).Hepatobiliary Surg Nutr2022https://conductscience.org/library/papers/35464283PubMed
335978604
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Liver Cancer2022https://conductscience.org/library/papers/35978604PubMed
429628281EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol2018https://conductscience.org/library/papers/29628281PubMed
533877527Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.Hepatol Int2021https://conductscience.org/library/papers/33877527PubMed
634143971Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol2021https://conductscience.org/library/papers/34143971PubMed
726146815World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.Hepatology2015https://conductscience.org/library/papers/26146815PubMed
830665869Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019https://conductscience.org/library/papers/30665869PubMed
922105822Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.J Clin Oncol2011https://conductscience.org/library/papers/22105822PubMed
1033317248Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects.Clin Mol Hepatol2021https://conductscience.org/library/papers/33317248PubMed
1133653656
Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
Acad Radiol2021https://conductscience.org/library/papers/33653656PubMed
1219725152Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients.World J Gastroenterol2009https://conductscience.org/library/papers/19725152PubMed
1329420221Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study.Clin Cancer Res2018https://conductscience.org/library/papers/29420221PubMed
1412479938Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis.Hepatol Res2002https://conductscience.org/library/papers/12479938PubMed
1534754838Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study.J Hepatocell Carcinoma2021https://conductscience.org/library/papers/34754838PubMed
1634185551Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.J Clin Oncol2021https://conductscience.org/library/papers/34185551PubMed
1735284529
Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study.
Hepatobiliary Surg Nutr2022https://conductscience.org/library/papers/35284529PubMed
1832897657Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors.Liver Transpl2021https://conductscience.org/library/papers/32897657PubMed
1929624699Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology2018https://conductscience.org/library/papers/29624699PubMed
2029995681Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients.Ann Surg2020https://conductscience.org/library/papers/29995681PubMed

See all 75 referencesDownload CSV of references

Cited by131

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 166 citations.

PMIDTitleJournalYearIn PapersSource
42967027Enhanced Efficacy of Thalidomide-Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study.MedComm (2020)2026https://conductscience.org/library/papers/42967027PubMed
42958661Xiaoyao San enhances the sensitivity of hepatocellular carcinoma to 5-fluorouracilautophagy modulation.J Tradit Chin Med2026https://conductscience.org/library/papers/42958661PubMed
42927357Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update.Cancer Manag Res2026https://conductscience.org/library/papers/42927357PubMed
42893081Construction of a Nomogram Integrating Magnetic Resonance Imaging Features and Ephrin-A3 Expression to Predict Postoperative Overall Survival in Hepatocellular Carcinoma.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42893081PubMed
42724514Akkermansia muciniphila attenuates apatinib resistance in hepatocellular carcinoma through NF-κB-mediated reprogramming of tumor-associated macrophages.Transl Cancer Res2026https://conductscience.org/library/papers/42724514PubMed
42592511A gradient core-shell microsphere to enable effective embolization of liver cancer via interventional therapy.Regen Biomater2026https://conductscience.org/library/papers/42592511PubMed
42588737The Controlling Nutritional Status Score as a Predictive Factor for Lung Metastasis in Patients with Hepatocellular Carcinoma After Hepatectomy.Cancers (Basel)2026https://conductscience.org/library/papers/42588737PubMed
42564342Prediction of early treatment response to drug-eluting beads chemoembolization for hepatocellular carcinoma using machine learning.Front Pharmacol2026https://conductscience.org/library/papers/42564342PubMed
42542804HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis.Ther Adv Med Oncol2026https://conductscience.org/library/papers/42542804PubMed
42540626Apatinib resistance mediated by IRF9 nuclear translocation in head and neck squamous cell carcinoma.iScience2026https://conductscience.org/library/papers/42540626PubMed
42445440The evolving landscape of early diagnosis for hepatocellular carcinoma: a bibliometric analysis of global research trends (2016-2026) based on WoSCC database.Transl Cancer Res2026https://conductscience.org/library/papers/42445440PubMed
42440203Huachansu triggers mitochondrial apoptosis and ER stress to inhibit hepatocellular carcinoma progression.Saudi Pharm J2026https://conductscience.org/library/papers/42440203PubMed
42433265Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.Liver Cancer2026https://conductscience.org/library/papers/42433265PubMed
42373443[Transitional and clinical practice pathways for whole-course management of hepatocellular carcinoma in the infectious diseases department].Zhonghua Gan Zang Bing Za Zhi2026https://conductscience.org/library/papers/42373443PubMed
42358545AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab.Front Oncol2026https://conductscience.org/library/papers/42358545PubMed
42326932Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma.Front Public Health2026https://conductscience.org/library/papers/42326932PubMed
42304258MRI radiomics and 90Y PET dosimetry for predicting hepatocellular carcinoma response after radioembolization.BMC Cancer2026https://conductscience.org/library/papers/42304258PubMed
42301580TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis.Eur Radiol Exp2026https://conductscience.org/library/papers/42301580PubMed
42292386Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study.Front Immunol2026https://conductscience.org/library/papers/42292386PubMed
42270819Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study.Sci Rep2026https://conductscience.org/library/papers/42270819PubMed

See all 131 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ACE1636PubTator's text mininghttps://conductscience.org/library/genes/1636NCBI Gene
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36545708

GET https://conductscience.org/api/papers/v1/36545708/references?page=2